Glenmark Pharmaceuticals saw the highest growth of 1.24% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.79% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Glenmark Pharmaceuticals‘s patent filings and grants. Buy the databook here.

Smarter leaders trust GlobalData

Glenmark Pharmaceuticals has been focused on protecting inventions in United States(US) with seven publications in Q2 2024

The United States(US) Patent Office dominates the patent filings and grants with nearly 42% filings and 100% grants. The United States(US), World Intellectual Property Organization(WIPO), Colombia(CO), and Australia(AU) patent Office are among the top ten patent offices where Glenmark Pharmaceuticals is filings its patents. Among the top granted patent authorities, Glenmark Pharmaceuticals has 100% of its grants in United States(US).

Regeneron Pharmaceuticals and Amgen could be the strongest competitors for Glenmark Pharmaceuticals

Patents related to rare diseases and nanomedicine lead Glenmark Pharmaceuticals's portfolio

Glenmark Pharmaceuticals has the highest number of patents in rare diseases followed by, nanomedicine. For rare diseases, nearly 100% of patents were filed and 50% of patents were granted in Q2 2024.

Multiple myeloma (kahler disease) related patents lead Glenmark Pharmaceuticals portfolio followed by prostate cancer, and non-small cell lung cancer

Glenmark Pharmaceuticals has highest number of patents in multiple myeloma (kahler disease) followed by prostate cancer, non-small cell lung cancer, lymphoma, and preleukemia. For multiple myeloma (kahler disease), nearly 4% of patents were filed and 2% of patents were granted in Q2 2024.

For comprehensive analysis of Glenmark Pharmaceuticals's filings and grants, buy the databook here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData patents database covers bibliographic from all 100+ patenting authorities. All patents are tagged to 18+ industries and 300+ sub-sectors based on technology classification, keywords, and associated companies. They are also tagged to various industries themes (100+) and technology domains (1800+) of focus.

Patents database further disambiguates assignee names (13m names) and associate corporate tree hierarchy in current/point in time ownerships (320k entities). GlobalData sources content directly from national patent offices on a weekly basis.